



61  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

*AF/TM*  
**MAIL STOP AMENDMENT**  
Attorney Docket No. 26797U

In re Application of:

|  |                 |               |
|--|-----------------|---------------|
| BRAUNGER et al.  | Conf. No.:      | 1055          |
| Serial No. 10/542,088  | Examiner:       | PAGONAKIS, A. |
| Filed: July 13, 2005   | Group Art Unit: | 1614          |
| <b>For: PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS</b> |                 |               |

**TRANSMITTAL LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Commissioner:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- (1) Transmittal Letter, one (1) page; and
- (2) Response and Amendment, nine (9) pages.

In the event this paper is not timely filed, Applicants petition for an appropriate extension of time. Please charge any fee deficiency or credit any overpayment to Deposit Account No. 14-0112.

Respectfully submitted,

**THE NATH LAW GROUP**



\_\_\_\_\_  
Gary M. Nath  
Registration No. 26,965  
Sheldon M. McGee  
Registration No. 50,454  
Customer No. 34375

Date: February 24, 2009  
**THE NATH LAW GROUP**  
112 South West Street  
Alexandria, Virginia 22314  
Tel: (703) 548-6284  
Fax: (703) 683-8396



Attorney Docket No.: 26797U

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

|  |                 |               |
|--|-----------------|---------------|
| BRAUNGER et al.  | Conf. No.:      | 1055          |
| Serial No. 10/542,088  | Examiner:       | PAGONAKIS, A. |
| Filed: July 13, 2005   | Group Art Unit: | 1614          |
| For: <b>PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS</b> |                 |               |

***RESPONSE AND AMENDMENT***

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This paper is filed responsive to the Official Action dated December 24, 2008, making a response due on March 24, 2009. Accordingly, this Response is timely filed.

**Amendments to the Claims** begins on page 2 of this paper.

**Remarks** begin on page 4 of this paper.

**A Conclusion** appears at page 9 of this paper.